A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Multi-National Phase II / III Follow-up Study to Assess Long-Term Efficacy and Safety of Three Different Dose Regimens of Oralgen Grass Pollen in Patients With Grass Pollen-Related Allergic Rhinoconjunctivitis (Follow-up Study to AB0602).

Trial Profile

A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Multi-National Phase II / III Follow-up Study to Assess Long-Term Efficacy and Safety of Three Different Dose Regimens of Oralgen Grass Pollen in Patients With Grass Pollen-Related Allergic Rhinoconjunctivitis (Follow-up Study to AB0602).

Completed
Phase of Trial: Phase II/III

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Grass pollen hypersensitivity; Rhinoconjunctivitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jan 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top